Neurotrophic factor therapy for Parkinson's disease

Progress in Brain Research

Volumn 184, Issue C, 2010, Pages 237-264

  Rangasamy, Suresh Babu ^a   Soderstrom, Katherine ^a   Bakay, Roy A E ^a   Kordower, Jeffrey H ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN; NEUROTROPHIN 3; NEUROTROPHIN 4; NEURTURIN; PLACEBO;

BOOK; CELL REGENERATION; CELL SURVIVAL; CELL THERAPY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; GENE THERAPY; HUMAN; MOTOR DYSFUNCTION; NERVE FIBER GROWTH; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 77957233908     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(10)84013-0     Document Type: Chapter

References (234)

1. Aebischer P., Goddard M., Sigmore A.P., Timpson R.L. Functional recovery in hemiparkinsonian primates transplanted with polymer-encapsulated PC12 cells. Experimental Neurology 1994, 126:151-158.
2. Ai Y., Markesbery W., Zhang Z., Grondin R., Elseberry D., Gerhardt G.A., et al. Intraputamenal infusion of GDNF in aged rhesus monkeys: Distribution and dopaminergic effects. Journal of Comparative Neurology 2003, 461(2):250-261.
3. Akerud P., Canals J.M., Snyder E.Y., Arenas E. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in mouse model of Parkinson's disease. Journal of Neuroscience 2001, 21:8108-8118.
4. Altar C.A., Boylan C.B., Fritsche M., Jones B.E., Jackson C., Wiegand S.J., et al. Efficacy of brain-derived neurotrophic factor and neurotrophin-3 on neurochemical and behavioral deficits associated with partial nigrostriatal dopamine lesions. Journal of Neurochemistry 1994, 63(2):1021-1032.
5. Altar C.A., Boylan C.B., Fritsche M., Jackson C., Hyman C., Lindsay R.M. The Neurotrophins NT-4/5 and BDNF augment serotonin, dopamine and GABAergic systems during behaviorally effective infusions to the substantia nigra. Experimental Neurology 1994, 130:31-40.
6. Altar C.A., Boylan C.B., Jackson C., Henshenson S., Miller J., Wiegand S., et al. Brain derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine in vivo. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:11347-11351.
7. Alterson R.F., Alterman A.L., Barde Y.A., Lindsay R.M. Brain-derived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture. Neuron 1990, 5(3):297-306.
8. Alterson R.F., Alterman A., Morissey D., Lindsay R.M. Effects of NT-4, BDNF, or NGF on the survival and phenotypic differentiation of septal cholinergic neurons in long-term cultures. Society for Neuroscience Abstract 1993, 19:666.
9. Apfel S.C. Administration to the central nervous system. Clinical application of neurotrophic factors 1997, 185-199. Lippincott Raven, Philadelphia. S.C. Apfel, T.R. Van de Water, S. Koszer (Eds.).
10. Apostolou A., Shen Y., Liang Y., Luo J., Fang S. Armet, a UPR-upregulated protein, inhibits cell proliferation and ER-stress induced cell death. Experimental Cell Research 2008, 314:2454-2467.
11. Ardelt A.A., Flaris N., Roth K.A. Neurotrophin-4 selectively promotes neuron survival in organotypic slices of mouse striatum. Society for Neuroscience Abstract 1993, 19(1):417.
12. Baloh R.H., Tansey M.G., Lampe P.A., Fahrner T.J., Enomoto H., Simburger K.S., et al. Artemin, a novel member of the GDNF Ligand family, supports peripheral and central neurons and signals through the GFRα3-RET Receptor Complex. Neuron 1998, 21:1291-1302.
13. Bankiewicz K.S., Eberling J.L., Kohutnicka M., Jagust W., Pivirotto P., Bringas J., et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Experimental Neurology 2000, 164(1):2-14.
14. Baquet Z.C., Bickford P.C., Jones K.R. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. Journal of Neuroscience 2005, 25:6251-6259.
15. Barde Y.A., Edgar D., Thoenen H. Purification of new neurotrophic factor from mammalian brain. EMBO Journal 1982, (1):549-553.
16. Bartus R.T., Herzog C.D., Bishop K., Ostrove J.M., Tuszynski M.H., Kordower J.H. Issues regarding gene therapy products for Parkinson's disease: The development of CERE-120 (AAV-NTN) as one reference point. Parkinsonism and Related Disorders 2007, 13:S469-S477.
17. Beckman C.M., Shan L., Zhang Y.J., Hoffer B.J., Leonard J.C., Vonsatel P., et al. Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: A real-time PCR study. Molecular and Cellular Endocrinology 2006, 252(1-2):160-166.
18. Beck K.D., Valverde J., Alexi T., Poulsen K., Motaff B., Vandlen R.A., et al. Mesencephalic dopamine neurons protected by GDNF from axotomy-induced degeneration in adult brain. Nature 1995, 335:479-489.
19. Behrstock S., Ebert A., McHugh J., Vosberg S., Moore J., Schneider B., et al. Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates. Gene Therapy 2006, 13(5):379-388.
20. Benraiss A., Chmielnicki E., Lerner K., Roh D., Goldman S.A. Adenoviral brain-derived neurotrophic factor induces both neostriatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult forebrain. Journal of Neuroscience 2001, 21(17):6718-6731.
21. Bensadoun J.C., Deglon N., Tseng J.L., Ridet J.L., Zurn A.D., Aebischer P. Lentiviral vectors as a gene delivery system in the mouse midbrain: Cellular and behavioral improvements in a 6-OHDA model of Parkinson's Disease using GDNF. Experimental Neurology 2000, 164(1):15-24.
22. Berkmeier L.R., Winslow J.W., Kaplan D.R., Nikolics K., Goeddel D.V., Rosenthal A. Neurotrophin-5: A novel neurotrophic factor that activates trk and trkB. Neuron 1991, 7:857-866.
23. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Journal of the Neurological Sciences 1973, 20(4):415-455.
24. Bilang-Bleuel A., Revah F., Colin P., Locquet I., Robert J.J., Mallet J., et al. Intrastriatal injection of an adenoviral vector expressing Glial cell line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson's Disease. Proceedings of the National Academy of Sciences of the United States of America, Brain Research 1997, 94:8818-8823.
25. Bjorklund A., Kirik D., Rosenblad C., Georgievska B., Lundberg C., Mandel R.J. Towards a neuroprotective gene therapy for Parkinson's Disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Research 2000, 886(1-2):82-98.
26. Blochl A., Sirrenberg C. Neurotrophins stimulate the release of dopamine from rat mesencephalic neurons via Trk and p75Lntr receptors. Journal of Biological Chemistry 1996, 271(35):21100-21107.
27. Borello M.G., Alberti L., Arighi E., Bongarzone I., Battistine C., Bardelli A., et al. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase C gamma. Molecular and Cellular Biology 1996, 16(5):2151-2163.
28. Broom J.D., Wills K.V., Lapchak P.A., Ghetti B., Camp L.L., Bayer S.A. Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons from the lethal action of the weaver gene: A quantitative immunocytochemical study. Developmental Brain Research 1999, 116(1):1-7.
29. Burazin T.C., Gundlach A.L. Localization of GDNF/neurturin receptor (c-ret, GFRalpha-1 and alpha-2) mRNAs in postnatal rat brain: Differential regional and temporal expression in hippocampus, cortex and cerebellum. Molecular Brain Research 1999, 73:151-171.
30. Bustos G., Abarca J., Bustos V., Riquelme E., Noriega V., Moya C., et al. NMDA receptors mediate an early up-regulation of brain derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease. Journal of Neuroscience Research 2009, 87(10):2308-2318.
31. Chaturvedi R.K., Shukla S., Seth K. Agarwal, A. K. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease. Neuroscience Letters 2006, 398:44-49.
32. Chen G., Bower K.A., Ma C., Fang S., Thiele C.J., Luo J. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB Journal 2004, 18:1162-1164.
33. Chiang Y.H., Borlongan C.V., Zhou F.C., Hoffer B.J., Wang Y. Transplantation of fetal kidney cells: Neuroprotection and neuroregeneration. Cell Transplantation 2005, 14:1-9.
34. Chiocco M.J., Harvey B.K., Wang Y., Hoffer B.J. Neurotrophic factors for the treatment of Parkinson's disease. Parkinsonism and Related Disorders 2007, 13:S321-S328.
35. Choi-Lundberg D.L., Lin Q., Chang Y.N., Hay C.M., Mohajeri H., Davidson B.L., et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997, 275:838-841.
36. Choi-Lundberg D.L., Lin Q., Schallert T., Crippens D., Davidson B.L., Chang Y.N., et al. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Experimental Neurology 1998, 154(2):261-275.
37. Chun H.S., Son J.J., Son J.H. Identification of potential compounds promoting BDNF production in nigral dopaminergic neurons: Clinical implication in Parkinson's disease. Molecular Neuroscience 2000, 11(3):511-514.
38. Clarke D.B., Wang Y.C., Bray G.M., Rasiminsky M., Aguayo A.J. Effect of neurotrophin-4 administration on the survival of axotomized retinal ganglion cells in adult rats. Society for Neuroscience 1994, 19(2):1104.
39. Cohen S., Levi-Montalcini R. Purification and properties of a nerve growth promoting factor isolated from mouse sarcoma 180. Cancer Research 1957, 17(1):15-20.
40. Conner B., Kozlowski D.A., Schallert T., Tillerson J.L., Davidson B.L., Bohn M.C. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Therapy 1999, 6(12):1936-1951.
41. Coppola V., Kucera J., Palko M., Lyons W., Fritzsch B., Tessarollo L. Dissection of NT3 functions in vivo by gene replacement strategy. Development 2001, 128(21):4315-4327.
42. Costa S., Iravani M.M., Pearce R.K., Jenner P. Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets. European Journal of Pharmacology 2001, 412:45-50.
43. Creedon D.J., Tansey M.G., Baloh R.H., Osborne P.A., Lampe P.A., Fahrner T.J., et al. Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:7018-7023.
44. Cui W., Allen N.D., Skynner M., Gusterson B., Clark A.J. Inducible ablation of astrocytes shows that these cells are required for neuronal survival in the adult brain. Glia 2001, 34(2):272-282.
45. Cunningham L.A., Su C. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. Experimental Neurology 2002, 174:230-242.
46. Date I., Shingo T., Ohmoto T., Emerich D.F. Long-term enhanced chromaffin cell survival and behavioral restoration in hemiparkinsonian rats with co-grafted polymer-encapsulated human NGF-secreting cells. Experimental Neurology 1997, 147:10-17.
47. Dedieu J.F., Vigne E., Torrent C., Jullien C., Mahfouz I., Caillaud J.M., et al. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. Journal of Virology 1997, 71(6):4626-4637.
48. Deglon N., Tseng J.L., Bensadoun J.C., Zurn A.D., Arsenijevic Y., Pereira de Almeida L., et al. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Human Gene Therapy 2000, 11(1):179-190.
49. Do Thi N.A., Saillour P., Ferrero L., Dedieu J.F., Mallet J., Paunio T. Delivery of GDNF by an E1, E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease. Gene Therapy 2004, 11:746-756.
50. Do Thi N.A., Saillour P., Ferrero L., Paunio T., Mallet J. Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson's disease?. Gene Therapy 2007, 14:441-450.
51. Ebendal T. NGF in CNS: Experimental data and clinical implications. Progress in Growth Factor Research 1989, 1(3):143-159.
52. Eberling J.L., Kens A.P., Pivirotto P., Beyer J., Bringas J., Federoff H.J., et al. Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Human. Gene Therapy 2009, 20:511-518.
53. Ericson C., Georgievska B., Lundberg C. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease. European Journal of Neuroscience 2005, 22:2755-2764.
54. Ernfors P., Kucera J., Lee K.F., Loring J., Jaenisch R. Studies on the physiological role of brain-derived neurotrophic factor and neurotrophin-3 in knockout mice. International Journal of Developmental Biology 1995, 39(5):799-807.
55. Eslamboli A., Cummings R.M., Ridley R.M., Baker H.F., Muzyczka N., Burger C., et al. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Experimental Neurology 2003, 184(1):536-548.
56. Espejo E.F., Gonzalez-Albo M.C., Moraes J.P., El Banoua F., Flores J.A., Caraballo I. Functional regeneration in a rat Parkinson's model after intrastriatal grafts of glial cell line-derived neurotrophic factor and transforming growth factor beta1-expressing extra adrenal chromaffin cells of the Zuckerkandl's organ. Journal of Neuroscience 2001, 21:9888-9895.
57. Feng L., Wang C.Y., Jiang H., Oho C., Dugich-Djordjevic M., Mei L., et al. Differential signaling of glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor in cultured ventral mesencephalic neurons. Neuroscience 1999, 93:265-273.
58. Fjord-Larsen L., Johansen J.L., Kusk P., Tornoe J., Gronborg M., Rosenblad C., et al. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Experimental Neurology 2005, 195:49-60.
59. Friedman W.J., Ibanez C.F., Hallbook F., Persson H., Cain L.D., Dreyfus C.F., et al. Differential actions of neurotrophins in the locus coeruleus and basal forebrain. Experimental Neurology 1993, 119:72-78.
60. Frim D.M., Uhler T.A., Galpren W.R., Beal M.F., Breakefield M.O., Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridium toxicity to dopaminergic neurons in the rat. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:5104-5108.
61. Fumagalli F., Racagni G., Riva M.A. Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease. Pharmacogenomics 2006, 6(2):95-104.
62. Galpern W.R., Frim D.M., Tatter S.B., Altar C.A., Beal M.F., Isacson O. Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in the MPP+ rat model of substantia nigra degeneration. Cell Transplantation 1996, 5:225-232.
63. Gash D.M., Zhang Z., Ai Y., Grondin R., Coffey R., Gerhardt G.A. Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Annals of Neurology 2005, 58:224-233.
64. Gash D.M., Zhang Z., Cass W.A., Ovadia A., Simmerman L., Martin D., et al. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. Journal of Comparative Neurology 1995, 363(3):345-358.
65. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380:252-255.
66. Gasmi M., Brandon E.P., Herzog C.D., Wilson A., Bishop K.M., Hofer E.K., et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiology of Disease 2007, 27:67-76.
67. Gasmi M., Herzog C.D., Brandon E.P., Cunningham J.J., Ramirez G.A., Ketchum E.T., et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Molecular Therapy 2007, 15:62-68.
68. Georgievska B., Kirik D., Bjorklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons by long lasting expression of glial cell line-derived neurotrophic factor in the striatum by lentiviral gene transfer. Experimental Neurology 2002, 177(2):461-474.
69. Georgievska B., Kirik D., Rosenblad C., Lundberg C., Bjorklund A. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 2002, 13:75-82.
70. Gerhardt G.A., Cass W.A., Huettl P., Brock S., Zhang Z., Gash D.A. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Research 1999, 817:163-171.
71. Gill S.S., Patel N.K., Hotton G.R., O'Sulllivan K., McCarter R., Bunnage M., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson's disease. Nature Medicine 2003, 9(5):589-595.
72. Glass D.J., Nye S.H., Hantzopoulos P., Macchi M.J., Squinto S.P., Goldfarb M., et al. TrkB mediates BDNF/NT-3-dependent survival and proliferation in fibroblasts lacking the low affinity NGF receptor. Cell 1991, 66:405-413.
73. Gotz R., Koster R., Winkler C., Raulf F., Lottspeich F., Schartl M., et al. Neurotrophin-6 is a new member of the nerve growth factor family. Nature 1994, 372:266-269.
74. Grondin R., Zhang Z., Yi A., Cass W.A., Maswood N., Andersen A.H., et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 2002, 125(Pt 10):2191-2201.
75. Gu S., Huang H., Bi J., Yao Y., Wen T. Combined treatment of neurotrophin-3 gene and neural stem cells is ameliorative to behavior recovery of Parkinson's disease rat model. Brian Research 2009, 1257:1-9.
76. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioral sensitization. Nature 2001, 411:86-89.
77. Hamilton J.F., Morrison P.F., Chen M.Y., Harvey-White J., Pernaute R.S., Phillips H., et al. Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin. Experimental Neurology 2001, 168(1):155-161.
78. Hebert M.A., Van Horne C.G., Hoffer B.J., Gerhardt G.A. Functional effects of GDNF in normal rat striatum: Presynaptic studies using in vivo electrochemistry and microdialysis. Journal of Pharmacology and Experimental Therapeutics 1996, 279:1181-1190.
79. Henderson C.E., Camu W., Mettling C., Gouin A., Poulsen K., Karihaloo M., et al. Neurotrophins promote motor neuron survival and are present in embryonic limb bud. Nature 1993, 363:266-270.
80. Herzog C.D., Brown L., Gammon D., Kruegel B., Li R., Wilson A., et al. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support CERE-120 for Parkinson's disease. Neurosurgery 2009, 64:602-613.
81. Herzog C.D., Dass B., Gasmi M., Bakay R., Stansell J., Tuszynski M.H., et al. Transgene expression, bioactivity, and safety of CERE-120 (AAV-Neurturin) following delivery to the monkey striatum. Molecular Therapy 2008, 16:1737-1744.
82. Herzog C.D., Dass B., Holden J.E., Stansell J., Gasmi M., Tuszynski M.H., et al. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Movement Disorders 2007, 22:1124-1132.
83. Hoane M.R., Gulwadi A.G., Morrison S., Hovanesian G., Lindnre M.D., Tao W. Differential in vivo effects of neurturin and glial cell line-derived neurotrophic factor. Experimental Neurology 1999, 160:235-243.
84. Hoffer B.J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., et al. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neuroscience Letters 1994, 182:107-111.
85. Horger B.A., Nishimura M.C., Armanini M.P., Wang L.C., Poulsen K.T., Rosenblad C., et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. Journal of Neuroscience 1998, 18:4929-4937.
86. Hornykiewicz O., Kish S.J. Biochemical pathophysiology of Parkinson's disease. Advances in Neurology 1987, 45:19-34.
87. Howells D.W., Porritt M.J., Wong J.Y., Batchelor P.E., Kalnins R., Hughes A.J., et al. Reduced BDNF and mRNA expression in the Parkinson's disease substantia nigra. Experimental Neurology 2000, 166(1):127-135.
88. Hudson J., Granholm A.C., Gerhardt G.A., Henry M.A., Hoffman A., Biddle P., et al. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Research Bulletin 1995, 36:425-432.
89. Hughes P.E., Alexi T., Walton M., Williams C.E., Dragunow M., Clark R.G., et al. Activity and injury-dependent expression of inducible trophic factors, growth factors, and apoptosis-related genes within the central nervous system. Progress in Neurobiology 1999, 57:421-450.
90. Hung H.C., Lee E.H.Y. The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP(+) toxicity: Role of BDNF gene expression. Molecular Brain Research 1996, 41:16-26.
91. Hurtig H., Joyce J., Sladek J.R., Trojanowski J.A. Postmortem analysis of adrenal-medulla-to-caudate autograft in a patient with Parkinson's disease. Annals of Neurology 1989, 25(6):607-614.
92. Hyman C., Hofer M., Barde Y.A., Juhasz M., Yancopoulos G.D., Squinto S.P., et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991, 350(6315):230-232.
93. Hyman C., Juhasz M., Jackson C., Wright P., Ip N.Y., Lindsay R.M. Overlapping and distinct actions of the neurotrophins BDNF, NT-3, and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. Journal of Neuroscience 1994, 14:335-347.
94. Ibanez C.F. Structure-function relationship in the neurotrophin family. Journal of Neurobiology 1994, 25(11):1349-1361.
95. Ibanez C.F. Emerging themes in structural biology of neurotrophic factors. Trends in Neurosciences 1998, 21(10):438-444.
96. Ip N.Y., Ibanez C.F., Nye S.H., McClain J., Jones P.F., Gies D.R., et al. Mammalian neurotrophin-4: Structure, chromosomal localization, tissue distribution and receptor specificity. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:3060-3064.
97. Ip N.Y., Yanping L., Yancopoulos G.D., Lindsay R.M. Cultured hippocampal neurons show responses to BDNF, NT-3, and NT-4 but not NGF. Journal of Neuroscience 1993, 13:3394-3405.
98. Jing S., Yu Y., Fang M., Hu Z., Holst P.L., Boone T., et al. GFRalpha-2 and GFRalpha-3 are two new receptors for ligands of the GDNF family. Journal of Biological Chemistry 1997, 272:33111-33117.
99. Johnston L.C., Eberling J., Piviroto P., Hadaczek P., Federoff H.J., Forsayeth J., et al. Clinically relevant effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Human Gene Therapy 2009, 20:497-510.
100. Jones K.R., Reichardt L.F. Molecular cloning of a human gene that is a member of the nerve growth factor family. Proceedings of the National Academy of Sciences of the United States of America 1990, 87(20):8060-8064.
101. Kaplan D.R., Miller F.D. Signal transduction by the neurotrophin receptors. Current Opinion in Cell Biology 1997, 9:213. -212.
102. Karamohamed S., Latourelle J.C., Racette B.A., Perlmutter J.S., Wooten G.F., Lew M., et al. BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD study. Neurology 2005, 65(11):1823-1825.
103. Kearns C.M., Gash D.M. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Research 1995, 672:104-111.
104. Kirik D., Rosenblad C., Bjorklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. European Journal of Neuroscience 2000, 12(11):3871-3882.
105. Kirik D., Rosenblad C., Bjorklund A., Mandel R.J. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. Journal of Neuroscience 2000, 20:4686-4700.
106. Klein R.L., Lewis M.H., Muzyczka N., Meyer E.M. Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer. Brain Research 1999, 847:314-320.
107. Klein R.D., Sherman D., Ho W.H., Stone D., Bennett G.L., Moffat B., et al. A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor. Nature 1998, 387:717-721.
108. Klein R., Silos-Santiago I., Smeyne R., Lira S., Brambilla R., Bryant S., et al. Disruption of the neurotrophin-3 receptor gene trkC eliminates Ia muscle afferents and results in abnormal movements. Nature 1994, 368:249-251.
109. Knusel B., Winslow J.W., Rosenthal A., Burton L.E., Seid D.P., Nikolics K., et al. Promotion of central cholinergic and dopaminergic neuron differentiation by brain derived neurotrophic factor but not neurotrophin 3. Proceedings of the National Academy of Sciences of the United States of America 1991, 88(3):961-965.
110. Koh J.Y., Gwag B.J., Lobner D., Choi D.W. Potentiated necrosis of cultured cortical neurons by neurotrophins. Science 1995, 268(5210):573-575.
111. Kohno R., Sawada H., Kawamoto Y., Uemura K., Shibasaki H., Shimohama S. BDNF is induced by wild-type alpha-synuclein but not by the two mutants, A30P or A53T, in glioma cell line. Biochemical and Biophysical Research Communications 2004, 318(1):113-118.
112. Kojima H., Abiru Y., Sakajira K., Watabe K., Ohishi N., Takamori M., et al. Adenovirus mediated transduction with human Glial cell line-derived neurotrophic factors gene prevents 1-methyl-4-phenyl, 1,2,3,6-tetrahydro-pyridine-induced dopamine depletion in striatum of mouse brain. Biochemical and Biophysical Research Communications 1997, 238:569-573.
113. Kordower J.H. In Vivo gene delivery of Glial cell line-derived neurotrophic factor for Parkinson's disease. Annals of Neurology 2003, 3:S120-S134.
114. Kordower J.H., Bloch J., Ma S.Y., Chu Y., Palfi S., Roitberg B.Z., et al. Lentiviral gene transfer to the nonhuman primate brain. Experimental Neurology 1999, 160(1):1-16.
115. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000, 290:767-773.
116. Kordower J.H., Herzog C.D., Dass B., Bakay R.A., Stansell J., Gasmi M., et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Annals of Neurology 2006, 60:706-715.
117. Kordower J.H., Palfi S., Chen E.Y., Ma S.Y., Sendera T., Cochran E.J., et al. Clinicopathological findings following intraventricular glial cell line-derived neurotrophic factor treatment in a patient with Parkinson's Disease. Annals of Neurology 1999, 46(3):419-424.
118. Kotzbauer P.T., Lampe P., Heuckeroth R.O., Golden J.P., Creedon D.J., Johnson E.M., et al. Neurturin, a relative of glial-cell-line derived neurotrophic factor. Nature 1996, 384:467-470.
119. Krieglstein K., Suter Crazzolara C., Fischer W.H., Unsicker K. TGF-beta superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP+ toxicity. EMBO Journal 1995, 14(4):736-742.
120. Lai K.O., Fu W.Y., Ip F.C.F., Ip N.Y. Cloning and expression of a novel neurotrophin, NT-7, from carp. Molecular and Cellular Neuroscience 1998, 11:64-76.
121. Lamballe F., Klein R., Barbacid M. TrkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell 1991, 66(5):967-979.
122. Lapchak P.A., Araujo D.M., Hefti F. BDNF and trkB mRNA expression in the rat hippocampus following entorhinal cortex lesions. Neuroreport 1993, 4:191-194.
123. Lapchak P.A., Miler P.J., Collins F., Jiao S. Glial cell line-derived neurotrophic factor attenuates behavioral deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: Comparison of intraventricular and intranigral delivery. Neuroscience 1997, 78:61-72.
124. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987, 237:1154-1162.
125. Levi-Montalcini R., Hamburger V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. Journal of Experimental Zoology 1951, 116(2):321-361.
126. Levi-Montalcini R., Hamburger V. A diffusible agent of mouse sarcoma, producing hyperplasia of sympathetic ganglia and hyperneurotization of viscera in the chick embryo. Journal of Experimental Zoology 1953, 123:233-288.
127. Levivier M., Przedborski S., Bencsics C., Kang U.J. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. Journal of Neuroscience 1995, 15:7810-7820.
128. Li H., He Z., Su T., Ma Y., Lu S., Dai C., et al. Protective action of recombinant neurturin on dopaminergic neurons in substantia nigra in rhesus monkey model of Parkinson's disease. Neurological Research 2003, 25(3):263-267.
129. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
130. Lindholm P., Peranen J., Andresso J.O., Kalkkinen N., Kokaia Z., Lindvall O., et al. MANF is widely expressed in mammalian tissues and differently regulated after ischemic and epileptic insults in rodent brain. Molecular and Cellular Neuroscience 2008, 39:356-371.
131. Lindholm P., Saarma M. Novel CDNF/MANF family of neurotrophic factors. Developmental Neurobiology 2009, 9:1-12.
132. Lindholm P., Voutilainen M.H., Lauren J., Peranen J., Leppanen V.M., Andressoo J.O., et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007, 448:73-77.
133. Lindsay R.M., Altar C.A., Cedarbaum J.M., Hyman C., Wiegand S.J. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease. Experimental Neurology 1993, 124(1):103-118.
134. Liu L.F., Lu G.Q., Li B., Chen S.D. Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease. Parkinsonism and Related Disorders 2007, 13:77-88.
135. Lo B.C., Deglon N., Pralong W., Aebischer P. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiology of Disease 2004, 17:283-289.
136. Lo B.C., Ridet J.L., Schneider B.L., Deglon N., Aebischer P. Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:10813-10818.
137. Lorigados L., Alvarez P., Pavon N., Serrano T., Blanco L., Macias R. NGF in experimental models of Parkinson disease. Molecular and Chemical Neuropathology 1996, 28(1-3):225-228.
138. Lorigados Pedre L., Pavon Fuentes N., Alvarez Gonzalez L., McRae A., Serrano Sanchez T., Blanco Lescano L., et al. Nerve growth factor levels in Parkinson disease and experimental parkinsonian rats. Brain Research 2002, 952:122-127.
139. Lorigados L., Sodestrom S., Ebendal T. Two-site enzyme immunoassay for beta NGF applied to human patient sera. Journal of Neuroscience Research 1992, 32(3):329-339.
140. Lucidi-Phillipi C.A., Gage F.H., Shults C.W., Jones K.R., Reichardt L.F., Kang U.J. Brain derived neurotrophic factor-transduced fibroblasts: Production of BDNF and effects of grafting to the adult rat brain. Journal of Comparative Neurology 1995, 354(3):361-376.
141. Maisonpierre P.C., Belluscio L., Squinto S., Ip N.Y., Furth M.E., Lindsay R.M., et al. Neurotrophin-3: A neurotrophic factor related to NGF and BDNF. Science 1990, 247:1446-1451.
142. Maisonpierre P.C., Le Beau M.M., Espinosa R., Ip N.Y., Belluscio L., de la Monte S.M., et al. Human and rat brain-derived neurotrophic factor and neurotrophin-3: Gene structures, distributions, and chromosomal localizations. Genomics 1991, 10(3):558-568.
143. Mandel R.J., Spratt S.K., Snyder R.O., Leff S.E. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(25):14083-14088.
144. Marks W.J., Ostrem J.L., Verhagen L., Starr P.A., Bakay R.A., Taylor R., et al. Safety and tolerability of intraputamenal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase I trial. Lancet Neurology 2008, 7(5):400-408.
145. Maswood N., Grondin R., Zhang Z., Stanford J.A., Surgener S.P., Gash D.M., et al. Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys. Neurobiology of Aging 2002, 23(5):881-889.
146. Mattson M.P. Neuroprotective strategies based on targeting of post-receptor signaling events. Neuroprotective signal transduction 1998, 301-335. Humana Press, Totown, NJ. M.P. Mattson (Ed.).
147. McGrath J., Lintz E., Hoffer B.J., Gerhardt G.A., Quintero E.M., Granholm A.C. Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion. Cell Transplantation 2002, 11:215-227.
148. Milbrandt J., de Sauvage F.J., Fahrner T.J., Baloh R.H., Leitner M.L., Tansey M.G., et al. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 1998, 20(2):245-253.
149. Miyoshi Y., Zhang Z., Ovadia A., Lapchak P.A., Collins F., Hilt D., et al. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Annals of Neurology 1997, 42(2):208-214.
150. Mizobuchi N., Hseki J., Kubota H., Tyokuni S., Nozaki J., Naitoh M., et al. ARMET is a soluble ER protein induced by the unfolded protein response via ERSE-II element. Cell Structure and Function 2007, 32:41-50.
151. Mogi M., Togari A., Kondo T., Mizuno Y., Kogure O., Kuno S., et al. Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains. Neuroscience Letters 2001, 300(3):179-181.
152. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., et al. Brain derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neuroscience Letters 1999, 270(1):45-48.
153. Momose Y., Murata M., Kobayashi K., Tachikawa M., Nakabayashi Y., Kanazawa I., et al. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Annals of Neurology 2002, 51:133-136.
154. Moore M.W., Klein R.D., Farinas I., Sauer H., Armanini M., Phillips H., et al. Renal and neuronal abnormalities in mice lacking GDNF. Nature 1996, 382:76-79.
155. Morse J.K., Wiegand S.J., Anderson K., You Y., Cai N., Carnahan J., et al. Brain derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection. Journal of Neuroscience 1993, 13(10):4146-4156.
156. Mufson E.J., Kroin J.S., Sendera T.J., Sobreviela T. Distribution and retrograde transport of trophic factors in the central nervous system: Functional implications for the treatment of neurodegenerative diseases. Progress in Neurobiology 1999, 57(4):451-458.
157. Murer M.G., Yan Q., Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain and in Alzheimer's disease and Parkinson's disease. Progress in Neurobiology 2001, 63(1):71-124.
158. Naldini L., Blomer U., Gage F.S., Trono D., Verma I.M. Efficient transfer, integration and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(21):11383-11388.
159. Nicole O., Ali C., Docagne F., Plawinski L., MacKenzie E.T., Vivien D., et al. Neuroprotection mediated by glial cell line-derived neurotrophic factor: Involvement of a reduction of NMDA-induced calcium influx by the mitogen-activated protein kinase pathway. Journal of Neuroscience 2001, 21(9):3024-3033.
160. Nicoletti F., Bruno V., Copani A., Casabona G., Knopfel T. Metabotropic glutamate receptors: A new target for the therapy of neurodegenerative disorders?. Trends in Neurosciences 1996, 19:267-271.
161. Nilsson A.S., Fainziliber M., Falck P., Ibanez C.F. Neurotrophin-7: A novel member of the neurotrophin family from the zebra fish. FEBS Letters 1998, 424:285-290.
162. Norsat C.A., Tomac A., Hoffer B.J., Olson L. Cellular and developmental patterns of expression of Ret and glial cell line-derived neurotrophic factor receptor alpha mRNAs. Experimental Brain Research 1997, 115:410-422.
163. Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws E.R., et al. ICV GDNF Study Group. Implanted intracerebroventricular. Glial cell line-dreived neurotrophic factor. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, I60(1):69-73.
164. Oiwa Y., Yoshimura R., Nakai K., Itakura T. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of Parkinson's disease. Brain Research 2002, 947:271-283.
165. Olson L., Backlund E.O., Ebendal T., Freedman R., Hamberger B., Hansson P., et al. Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease. One-year follow-up of first clinical trial. Archives of Neurology 1991, 48:373-381.
166. Palfi S., Leventhal L., Chu Y., Ma S.Y., Emborg M., Bakay R., et al. Lentiviral delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. Journal of Neuroscience 2002, 22(12):4942-4954.
167. Palgi M., Lindstrom R., Peranen J., Piepponen T.P., Saarma M., Heino T.I. Evidence that DmMANF is an invertebrate neurotrophic factor supporting dopaminergic neurons. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(7):2429-2434.
168. Park K.W., Eglitis M.A., Mouradian M.M. Protection of nigral neurons by GDNF-engineered marrow cell transplantation. Neuroscience Research 2001, 40:315-323.
169. Parkinson's Disease Foundation. Presented at , 2009. http://www.pdf.org.
170. Parsian A., Sinha R., Racette B., Zhao J.H., Perlmutter J.X. Association of a variation in the promoter region of the brain derived neurotrophic factor gene with familial Parkinson's disease. Parkinsonism and Related Disorders 2004, 10:213-219.
171. Patapoutian A., Reichardt L.F. Trk receptors: Mediators of neurotrophin action. Current Opinion in Neurobiology 2001, 11(3):272-280.
172. Patel N.K., Bunnage M., Plaha P., Svendsen C.N., Heywood P., Gill S.S. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two year outcome study. Annals of Neurology 2005, 57:298-302.
173. Peterson A.L., Nutt J.G. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics 2008, 5:270-280.
174. Peterson D.I., Price M.L., Small C.S. Autopsy findings in a patient who had an adrenal-to-brain transplant for Parkinson's disease. Neurology 1989, 39:235-238.
175. Petrova P.S., Raibekas A., Pevsner J., Vigo N., Anafi M., Moore M.K., et al. MANF: A new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. Journal of Molecular Neuroscience 2003, 20:173-187.
176. Petrova P.S., Raibekas A., Pevsner J., Vigo N., Anafi M., Moore M.K., et al. Discovering novel phenotype-selective neurotrophic factors to treat neurodegenerative diseases. Progress in Brain Research 2004, 146:168-183.
177. Rosenblad C., Gronborg M., Hansen C., Blom N., Meyer M., Johansen J., et al. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin. Molecular and Cellular Neuroscience 2000, 19(2):199-214.
178. Rosenblad C., Kirik D., Bjorklund A. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Experimental Neurology 2000, 161(2):503-516.
179. Rosenblad C., Kirik D., Devaux B., Mofat B., Phillips H.S., Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. European Journal of Neuroscience 1999, 11:1554-1566.
180. Rosenthal A., Goeddel D.V., Nguyen T., Lewis M., Shih A., Laramee G.R., Nikolics K., Winslow J.W. Primary structure and biological activity of a novel human neurotrophic factor. Neuron 1990, 4:767-773.
181. Sachs C., Jonsson G., Heikkila R., Cohen G. Control of the neurotoxicity of 6-hydroxydopamine by intraneuronal noradrenaline in rat iris. Acta Physiologica Scandinavica 1975, 93:345-351.
182. Salinas M., Diaz R., Abraham N.G., Ruiz de Galarreta C.M., Cuadrado A. Nerve growth factor protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a phosphatidylinositol 3-kinase-dependent manner. Journal of Biological Chemistry 2003, 3898-13904.
183. Salvatore M.F., Ai Y., Fischer B., Zhang A.M., Grondin R.C., Zhang A., et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Experimental Neurology 2006, 202(2):497-505.
184. Sanchez M.P., Silos-Santiago I., Frisen J., He B., Lira S.A., Barbacid M. Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 1996, 382:70-73.
185. Sanicola M., Hession C., Worley D., Carmillo C., Ehrenfels L., Walus L., et al. Glial cell line-derived neurotrophic factor-dependent cell-surface accessory proteins. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:6238-6243.
186. Sauer H., Fischer W., Nikkhah G., Wiegand S.J., Brundin P., Lindsay R.M., et al. Brain derived neurotrophic factor enhances function rather than survival of intrastriatal dopamine cell-rich grafts. Brain Research 1993, 626:37-44.
187. Sauer H., Rosenblad C., Bjorklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:8935-8939.
188. Sautter J., Tseng J.L., Braguglia D., Aesbischer P., Spenger C., Seiler R.W., et al. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Experimental Neurology 1998, 149:230-236.
189. Shimoke K., Chiba H. Nerve growth factor prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3 like activity using PC12 cells: Relevance to therapeutical application for Parkinson's disease. Journal of Neuroscience Research 2001, 63:402-409.
190. Shridhar V., Richard S., Shridhar R., Mullins C., Bostick L., Sakr W., et al. A gene from human chromosomal band 3p21.1 encodes a highly conserved arginine-rich protein and is mutated in renal cell carcinomas. Oncogene 1996, 12(9):1931-1939.
191. Shults C.W., Kimber T., Altar C.A. BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine. Neuroreport 1995, 30:1109-1112.
192. Siegel G.J., Chauhan N.B. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Research Reviews 2000, 33:199-227.
193. Silani V., Falini A., Strada O., Pizzuti A., Pezzoli G., Motti E.D., et al. Effect of nerve growth factor in adrenal autografts in parkinsonism. Annals of Neurology 1990, 27(3):341-342.
194. Singh S., Ahmad R., Mathur D., Sagar R.K., Krishna B. Neuroprotective effect of BDNF in young and aged 6-OHDA treated rat model of Parkinson disease. Indian Journal of Experimental Biology 2006, 44(9):699-704.
195. Slevin J.T., Gash D.M., Smith C.D., Gerhardt G.A., Kryscio R., Chebrolu H., et al. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson's disease: Response to 1 year of treatment and 1 year of withdrawal. Journal of Neurosurgery 2007, 106(4):614-620.
196. Snider W.D. Functions of the neurotrophins during nervous system development: What the knockouts are teaching us. Cell 1994, 77:627-638.
197. Sofroniew M.V., Howe C.L., Mobley W.C. Nerve growth factor signaling, neuroprotection, and neural repair. Annual Review of Neuroscience 2001, 24:1217-1281.
198. Sonasolla P.K., Albers D.S., Zeevalk G.D. Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism. Amino Acids 1998, 14:69-74.
199. Spina M.B., Squinto S.P., Miller J., Lindsay R.M., Hyman C. Brain derived neurotrophic factor protects dopamine neurons against 6-hydroxydopmaine and N-methyl-4-phenylpyridium ion toxicity: Involvement of the glutathione system. Journal of Neurochemistry 1992, 59:99-106.
200. Squinto S.P., Stitt T.N., Aldrich T.H., Davis S., Bianco S.M., Radziejewski C., et al. TrkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor. Cell 1991, 65:885-893.
201. Stromberg I., Ebendal T., Olson L., Hoffer B. Chromaffin grafts: survival and nerve fiber formation as a function of donor, age, nerve growth factor and host sympathetic denervation. Neural transplantation: from molecular basis to clinical applications. Program Brain Research 1990, 82:87-94. Elsevier, Amsterdam. S.B. Dunnett &, S.J. Richards (Eds.).
202. Stromberg I., Wetmore C.J., Ebendal T., Ernfors P., Perssons H., Olson L. Rescue of basal forebrain cholinergic neurons after implantation of genetically modified cells producing recombinant NGF. Journal of Neuroscience Research 1990, 25:405-411.
203. Sun M., Kong L., Wang X., Lu X.G., Gao Q., Geller A.I. Comparison of the capability of GDNF, BDNF, or both to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Research 2005, 1052:119-129.
204. Suvanto P., Hiltunen J.O., Arumae U., Moshnyakov M., Sariola H., Sainio K., et al. Localization of glial cell derived-neurotrophic factor (GDNF) mRNA in embryonic rat by in situ hybridization. European Journal of Neuroscience 1996, 8:816-822.
205. Tessarollo L. Pleiotropic functions of neurotrophins in development. Cytokine Growth Factor Reviews 1998, 9(2):125-137.
206. Tessarollo L., Tsoulfas P., Martin-Zanca D., Gilbert D., Jenkins N., Copeland N., et al. TrkC, a receptor for neurotrophin-3, is widely expressed in the developing nervous system and in non-neuronal tissues. Development 1993, 118:463-475.
207. Tessarollo L., Vogel K., Palko M., Reid S., Parada L. Targeted mutation in the neurotrophin-3 gene results in loss of muscle sensory neurons. Proceedings of the National Academy of Sciences of the United States of America 1994, 91(25):11844-11848.
208. Timm D.E., Ross A.H., Neet K.E. Circular dichroism and crosslinking studies of the interaction between four neurotrophins and the extracellular domain of the low-affinity neurotrophin receptor. Protein Science 1994, 3(3):451-458.
209. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373:335-339.
210. Tresco P.A., Winn S.R., Tan S., Jaeger C.B., Greene L.A., Aebischer P. Polymer-encapsulated PC 12 cells: Long-term survival and associated reduction in lesion-induced rotational behavior. Cell Transplantation 1992, 1:255-264.
211. Trupp M., Scott R., Whittemore S.R., Ibanez C.F. Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. Journal of Biological Chemistry 1999, 274(39):20885-20894.
212. Tseng J.L., Baetge E.E., Zurn A.D., Aesbischer P. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. Journal of Neuroscience 1997, 17(1):325-333.
213. Tseng J.L., Bruhn S.L., Zurn A.D., Aebischer P. Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy. Neuroreport 1998, 9:1817-1822.
214. Tuszynski M.H. Neurotrophic factors. CNS regeneration: Basic science and clinical advances 1999, 109-158. Academic Press, New York. M.H. Tuszynski, J.H. Kordower (Eds.).
215. Van Weeing D.H., Bos J.L. Signal transduction by the receptor tyrosine kinase Ret. Recent Results in Cancer Research 1998, 154:271-281.
216. Ventimiglia R., Mather P.E., Jones B.E., Lindsay R.M. The neurotrophins BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. European Journal of Neuroscience 1995, 7(2):213-222.
217. von Bohlen und Halbach O., Minichiello L., Unsicker K. Haploin-sufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra. FASEB Journal 2005, 19:1740-1742.
218. Voutilainen M.H., Back S., Porsti E., Toppinen L., Lindgren L., Lindholm P., et al. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. Journal of Neuroscience 2009, 29(30):9651-9659.
219. Wang L., Muramatsu S., Lu Y., Ikeguchi K., Fujimoto K., Okada T., et al. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Therapy 2002, 9(6):381-389.
220. Weidner N., Blesch A., Grill R.J., Tuszynski M.H. Nerve growth factor hypersecreting Schwann cell grafts augment and guide spinal cord axonal growth and remyelinate central nervous system axons in a phenotypically appropriate manner that correlates with expression of L1. Journal of Comparative Neurology 1999, 4131:495-506.
221. Widenfalk J., Nosrat C., Tomac A., Westphal H., Hoffer B., Olson L. Neurturin and glial cell line derived neurotrophic factor receptor-beta (GDNFR-beta), novel proteins related to GDNF and GDNFR-alpha with specific cellular patterns of expression suggesting roles in the developing and adult nervous system and in peripheral organs. Journal of Neuroscience 1997, 17:8506-8519.
222. Widmer H.R., Hefti F. Neurotrophin-4 promotes survival and differentiation of rat striatal neurons developing in culture. European Journal of Neuroscience 1994, 6(11):1669-1679.
223. Worby C.A., Vega Q.C., Zhao Y., Chao H.H., Seasholtz A.F., Dixon J.E. Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen activated protein kinase. Journal of Biological Chemistry 1996, 271(39):23619-23622.
224. Yang F., Feng L., Zheng F., Johnson S.W., Du J., Shen L., et al. GDNF acutely modulates excitability and A-type K(+) channels in midbrain dopaminergic neurons. Nature Neuroscience 2001, 4(11):1071-1078.
225. Yasuhara T., Matsukawa N., Hara K., Yu G., Xu L., Maki M., et al. Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson's disease. Journal of Neuroscience 2006, 26(48):12497-12511.
226. Ye M., Wang X.J., Zhang Y.H., Lu G.Q., Liang L., Xu J.Y., et al. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease. Brain Research 2007, 1142:206-216.
227. Yoshimoto Y., Lin Q., Collier T.J., Frim D.M., Breakefield X.O., Bohn M.C. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. Brain Research 1995, 691:25-36.
228. Yurek D.M., Lu W., Hipkens S., Wiegand S.J. BDNF enhances the functional reinnervation of the striatum by grafted fetal dopamine neurons. Experimental Neurology 1996, 137(1):105-118.
229. Zhang X., Andren P.E., Svenningsson P. Repeated L-DOPA treatment increases c-fos and BDNFs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson's disease. Brain Research 2006, 1095:207-210.
230. Zhang Z., Miyoshi Y., Lapchak P.A., Collins F., Hilt D., Lebel C., et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. Journal of Pharmacology and Experimental Therapeutics 1997, 282(3):1396-1401.
231. Zheng J.S., Tang L.L., Zheng S.S., Zhan R.Y., Zhou Y.Q., Goudreau J., et al. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease. Molecular Brain Research 2005, 134:155-161.
232. Zhou L., Baumgartner B., Hill-Felberg S., McGowen L., Shine H. Neurotrophin-3 expressed in situ induces axonal plasticity in the adult injured spinal cord. Journal of Neuroscience 2003, 23(4):1424-1431.
233. Zhou C., Xiao C., Commissiong J.W., Krnjevic K., Ye J.H. Mesencephalic astrocyte-derived neurotrophic factor enhances nigral gamma-aminobutyric acid release. Neuroreport 2006, 293-297.
234. Zigova T., Pencea V., Wiegand S.J., Luskin M.B. Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb. Molecular and Cellular Neuroscience 1998, 11(4):234-245.